Press release from Xeris:
Apparently one of the goals of the study was providing additional for European marketing authorization. Do the European regulation agencies require more evidence than the FDA? “Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use, stable liquid glucagon”
This article has a chart comparing Xeris’s Gvoke pen and syringe with a regular glucagon kit:
There’s also a figure with the instructions for the auto-injector administration procedure. I noticed that in contrast with the Epipen, the more conical tip of the pen is not the needle end and that the safety cap is on the needle end instead of the other. I wonder if this might cause confusion among people familiar with the Epipen.